---
document_datetime: 2025-12-29 10:38:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/actrapid.html
document_name: actrapid.html
version: success
processing_time: 0.1056142
conversion_datetime: 2025-12-29 21:47:34.822844
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Actrapid

[RSS](/en/individual-human-medicine.xml/66775)

##### Authorised

This medicine is authorised for use in the European Union

human insulin (rDNA) Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Actrapid](#news-on)
- [More information on Actrapid](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Actrapid. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Actrapid.

Expand section

Collapse section

## What is Actrapid?

Actrapid is a solution for injection that contains the active substance human insulin. It is available as vials, cartridges (Penfill) or prefilled pens (NovoLet, InnoLet or FlexPen).

## What is Actrapid used for?

Actrapid is used to treat diabetes.

The medicine can only be obtained with a prescription.

## How is Actrapid used?

Actrapid is given by injection under the skin in the thigh, the abdominal wall (at the front of the waist), the deltoid region (shoulder) or the gluteal region (buttocks). The patient's blood glucose (sugar) should be tested regularly to find the lowest effective dose.

The usual dose is between 0.3 and 1.0 international units (IU) per kilogram body weight per day. Actrapid is given 30 minutes before a meal. Actrapid is a fast-acting insulin and may be used with intermediate or long-acting insulins. Actrapid may also be given intravenously (into a vein) but only by a doctor or a nurse.

## How does Actrapid work?

Diabetes is a disease in which the body does not produce enough insulin to control the blood glucose or when the body is unable to use insulin effectively. Actrapid is a replacement insulin that is very similar to the insulin made by the pancreas.

The active substance in Actrapid, human insulin, is produced by a method known as 'recombinant technology': the insulin is made by a yeast that has received a gene (DNA), which makes it able to produce insulin. The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the blood glucose, the symptoms and complications of diabetes are reduced.

## How has Actrapid been studied?

Actrapid has been studied in patients with type-1 diabetes, when the pancreas cannot produce insulin (two studies involving 1,954 patients), and type-2 diabetes, when the body is unable to use insulin effectively (one study involving 182 patients). The studies compared Actrapid with another replacement insulin called insulin aspart over six months by measuring the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached. HbA1c gives an indication of how well the blood glucose is controlled.

## What benefit has Actrapid shown during the studies?

HbA1c levels remained fairly steady over the six months of treatment with Actrapid.

## What is the risk associated with Actrapid?

The most common side effect with Actrapid (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels). For the full description of all side effects reported with Actrapid, see the package leaflet.

Actrapid must not be used in people who are hypersensitive to human insulin or any of the other ingredients.

## Why has Actrapid been approved?

The CHMP decided that Actrapid's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Actrapid

The European Commission granted a marketing authorisation valid throughout the European Union for Actrapid on 7 October 2002.

For more information about treatment with Actrapid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Actrapid : EPAR - Summary for the public

English (EN) (73.53 KB - PDF)

**First published:** 04/02/2008

**Last updated:** 28/08/2013

[View](/en/documents/overview/actrapid-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-828)

български (BG) (99.69 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/bg/documents/overview/actrapid-epar-summary-public_bg.pdf)

español (ES) (72.51 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/es/documents/overview/actrapid-epar-summary-public_es.pdf)

čeština (CS) (118.81 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/cs/documents/overview/actrapid-epar-summary-public_cs.pdf)

dansk (DA) (72.49 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/da/documents/overview/actrapid-epar-summary-public_da.pdf)

Deutsch (DE) (72.74 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/de/documents/overview/actrapid-epar-summary-public_de.pdf)

eesti keel (ET) (71.52 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/et/documents/overview/actrapid-epar-summary-public_et.pdf)

ελληνικά (EL) (98.82 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/el/documents/overview/actrapid-epar-summary-public_el.pdf)

français (FR) (73.07 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/fr/documents/overview/actrapid-epar-summary-public_fr.pdf)

italiano (IT) (72.11 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/it/documents/overview/actrapid-epar-summary-public_it.pdf)

latviešu valoda (LV) (93.91 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/lv/documents/overview/actrapid-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (93.93 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/lt/documents/overview/actrapid-epar-summary-public_lt.pdf)

magyar (HU) (91.9 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/hu/documents/overview/actrapid-epar-summary-public_hu.pdf)

Malti (MT) (97.22 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/mt/documents/overview/actrapid-epar-summary-public_mt.pdf)

Nederlands (NL) (72.18 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/nl/documents/overview/actrapid-epar-summary-public_nl.pdf)

polski (PL) (96.83 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/pl/documents/overview/actrapid-epar-summary-public_pl.pdf)

português (PT) (72.36 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/pt/documents/overview/actrapid-epar-summary-public_pt.pdf)

română (RO) (93.47 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/ro/documents/overview/actrapid-epar-summary-public_ro.pdf)

slovenčina (SK) (117.46 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/sk/documents/overview/actrapid-epar-summary-public_sk.pdf)

slovenščina (SL) (88.01 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/sl/documents/overview/actrapid-epar-summary-public_sl.pdf)

Suomi (FI) (71.47 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/fi/documents/overview/actrapid-epar-summary-public_fi.pdf)

svenska (SV) (65.31 KB - PDF)

**First published:**

04/02/2008

**Last updated:**

28/08/2013

[View](/sv/documents/overview/actrapid-epar-summary-public_sv.pdf)

Actrapid : EPAR - Risk-management-plan summary

English (EN) (52.18 KB - PDF)

**First published:** 20/03/2018

**Last updated:** 16/06/2020

[View](/en/documents/rmp-summary/actrapid-epar-risk-management-plan-summary_en.pdf)

## Product information

Actrapid : EPAR - Product Information

English (EN) (1.01 MB - PDF)

**First published:** 18/02/2009

**Last updated:** 21/10/2020

[View](/en/documents/product-information/actrapid-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-31)

български (BG) (1.27 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/bg/documents/product-information/actrapid-epar-product-information_bg.pdf)

español (ES) (1.04 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/es/documents/product-information/actrapid-epar-product-information_es.pdf)

čeština (CS) (1.14 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/cs/documents/product-information/actrapid-epar-product-information_cs.pdf)

dansk (DA) (1.05 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/da/documents/product-information/actrapid-epar-product-information_da.pdf)

Deutsch (DE) (1.06 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/de/documents/product-information/actrapid-epar-product-information_de.pdf)

eesti keel (ET) (1.01 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/et/documents/product-information/actrapid-epar-product-information_et.pdf)

ελληνικά (EL) (1.24 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/el/documents/product-information/actrapid-epar-product-information_el.pdf)

français (FR) (1.06 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/fr/documents/product-information/actrapid-epar-product-information_fr.pdf)

hrvatski (HR) (1.16 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/hr/documents/product-information/actrapid-epar-product-information_hr.pdf)

íslenska (IS) (1.01 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/is/documents/product-information/actrapid-epar-product-information_is.pdf)

italiano (IT) (1.17 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/it/documents/product-information/actrapid-epar-product-information_it.pdf)

latviešu valoda (LV) (1.19 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/lv/documents/product-information/actrapid-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.46 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/lt/documents/product-information/actrapid-epar-product-information_lt.pdf)

magyar (HU) (1.2 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/hu/documents/product-information/actrapid-epar-product-information_hu.pdf)

Malti (MT) (1.07 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/mt/documents/product-information/actrapid-epar-product-information_mt.pdf)

Nederlands (NL) (1.02 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/nl/documents/product-information/actrapid-epar-product-information_nl.pdf)

norsk (NO) (1022.26 KB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/no/documents/product-information/actrapid-epar-product-information_no.pdf)

polski (PL) (1.31 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/pl/documents/product-information/actrapid-epar-product-information_pl.pdf)

português (PT) (1.05 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/pt/documents/product-information/actrapid-epar-product-information_pt.pdf)

română (RO) (1.19 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/ro/documents/product-information/actrapid-epar-product-information_ro.pdf)

slovenčina (SK) (1.18 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/sk/documents/product-information/actrapid-epar-product-information_sk.pdf)

slovenščina (SL) (1.12 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/sl/documents/product-information/actrapid-epar-product-information_sl.pdf)

Suomi (FI) (1.03 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/fi/documents/product-information/actrapid-epar-product-information_fi.pdf)

svenska (SV) (1.02 MB - PDF)

**First published:**

18/02/2009

**Last updated:**

21/10/2020

[View](/sv/documents/product-information/actrapid-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/1901 24/09/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Actrapid : EPAR - All Authorised presentations

English (EN) (116.22 KB - PDF)

**First published:** 03/04/2006

**Last updated:** 28/08/2013

[View](/en/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-713)

български (BG) (148.85 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/bg/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_bg.pdf)

español (ES) (117.2 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/es/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_es.pdf)

čeština (CS) (135.25 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/cs/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (121.89 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/da/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (118.68 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/de/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (134.83 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/et/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (138.26 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/el/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_el.pdf)

français (FR) (134.78 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/fr/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (120.52 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/is/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_is.pdf)

italiano (IT) (116.79 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/it/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (139.22 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/lv/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (152.2 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/lt/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (157.35 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/hu/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (155.35 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/mt/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (114.54 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/nl/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (117.17 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/no/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_no.pdf)

polski (PL) (153.47 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/pl/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_pl.pdf)

português (PT) (117.48 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/pt/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_pt.pdf)

română (RO) (147.1 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/ro/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (135.83 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/sk/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (132.32 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/sl/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (116.37 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/fi/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (136.24 KB - PDF)

**First published:**

03/04/2006

**Last updated:**

28/08/2013

[View](/sv/documents/all-authorised-presentations/actrapid-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Actrapid Active substance human insulin International non-proprietary name (INN) or common name human insulin (rDNA) Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code A10AB01

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Treatment of diabetes mellitus.

## Authorisation details

EMA product number EMEA/H/C/000424 Marketing authorisation holder

Novo Nordisk A/S

Novo Allé

Marketing authorisation issued 07/10/2002 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Actrapid : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (223.72 KB - PDF)

**First published:** 18/02/2009

**Last updated:** 21/10/2020

[View](/en/documents/procedural-steps-after/actrapid-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Actrapid : EPAR - Procedural steps taken before authorisation

English (EN) (90.13 KB - PDF)

**First published:** 03/04/2006

**Last updated:** 03/04/2006

[View](/en/documents/procedural-steps/actrapid-epar-procedural-steps-taken-authorisation_en.pdf)

Actrapid : EPAR - Scientific Discussion

English (EN) (367.53 KB - PDF)

**First published:** 03/04/2006

**Last updated:** 03/04/2006

[View](/en/documents/scientific-discussion/actrapid-epar-scientific-discussion_en.pdf)

#### News on Actrapid

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022) 22/04/2022

#### More information on Actrapid

- [Insulin (human insulin) (various short-, rapid-, intermediate-, mixed- and long-acting forms) - supply shortage](/en/medicines/human/shortages/insulin-human-insulin-various-short-rapid-intermediate-mixed-long-acting-forms)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 21/10/2020

## Share this page

[Back to top](#main-content)